Details
Stereochemistry | ACHIRAL |
Molecular Formula | Cr |
Molecular Weight | 51.9961 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 3 |
SHOW SMILES / InChI
SMILES
[Cr+3]
InChI
InChIKey=BFGKITSFLPAWGI-UHFFFAOYSA-N
InChI=1S/Cr/q+3
Molecular Formula | Cr |
Molecular Weight | 51.9961 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0004714 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15924436 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CHROMIUM Approved UseChromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. Launch Date2005 |
PubMed
Title | Date | PubMed |
---|---|---|
Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity. | 1996 Mar |
|
Thirteen-week subchronic rat inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic oxide, and basic chromium sulfate. | 1999 Dec |
|
The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment. | 2017 Sep 21 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:32:21 GMT 2023
by
admin
on
Fri Dec 15 16:32:21 GMT 2023
|
Record UNII |
X1N4508KF1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C68245
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1546418
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | RxNorm | ||
|
27668
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
49544
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
X1N4508KF1
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
DTXSID2023981
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
DB14525
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
X1N4508KF1
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
C68246
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY | |||
|
16065-83-1
Created by
admin on Fri Dec 15 16:32:22 GMT 2023 , Edited by admin on Fri Dec 15 16:32:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |